Deregulated Expression of Candidate MicroRNAs and BRCA Mutations Frequency in Breast Cancer Patients

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Mahmoud Said ◽  
Ibrahim Abd Elsalam ◽  
Hala ElDesouki ◽  
Amany Hilal ◽  
Hanan Nassar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Brca Mutations

Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations

2011 ◽  
Vol 202 (3) ◽  
pp. 298-302 ◽  
Author(s):  
Marissa Howard-McNatt ◽  
Rebecca W. Schroll ◽  
Gail J. Hurt ◽  
Edward A. Levine
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prophylactic Mastectomy ◽  
Contralateral Prophylactic Mastectomy ◽  
Breast Cancer Patients ◽  
Brca Mutations

scholarly journals The prevalence of ataxia telangiectasia mutated (ATM) variants in patients with breast cancer patients: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Masoumeh Moslemi ◽  
Maryam Vafaei ◽  
Pouria Khani ◽  
Marzieh Soheili ◽  
Reza Nedaeinia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Breast Cancer Patients ◽  
Ataxia Telangiectasia Mutated ◽  
Brca Mutations ◽  
Cross Sectional ◽  
Pooled Prevalence ◽  
Atm Gene ◽  
The Relationship

AbstractBreast cancer is the most common cancer in women, and its high mortality has become one of the biggest health problems globally. Several studies have reported an association between breast cancer and ATM gene variants. This study aimed to demonstrate and analyze the relationship between ATM gene polymorphisms and breast cancer prevalence rate. A systematic literature review was undertaken using the following databases: Medline (PubMed), Web of sciences, Scopus, EMBASE, Cochrane, Ovid, and CINHAL to retrieve all cross-sectional studies between January 1990 and January 2020, which had reported the frequency of ATM variants in patients with breast cancer. A random-effects model was applied to calculate the pooled prevalence with a 95% confidence interval. The pooled prevalence of ATM variants in patients with breast cancer was 7% (95% CI: 5−8%). Also, the pooled estimate based on type of variants was 6% (95% CI: 4−8%; I square: 94%; P: 0.00) for total variants¸ 0% (95% CI: 0−1%; I square: 0%; P: 0.59) for deletion variants, 12% (95% CI: 7−18%; I square: 99%; P: 0.00) for substitution variants, and 2% (95% CI: 4−9%; I square: 67%; P: 0.08) for insertion variants. This meta-analysis showed that there is a significant relationship between ATM variants in breast cancer patients. Further studies are required to determine which of the variants of the ATM gene are associated with BRCA mutations.

Prevalence of BRCA mutations in a cohort of young high-risk breast cancer patients

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 9662-9662 ◽  
Author(s):  
B. Bahadini ◽  
J. Herzog ◽  
G. Somlo ◽  
P. Frankel ◽  
S. Sand ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Brca Mutations ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

scholarly journals Is fertility preservation suggested in breast cancer patients with BRCA mutations

2018 ◽  
Vol 110 (4) ◽  
pp. e189 ◽  
Author(s):  
E. Porcu ◽  
L. Cipriani ◽  
G. Damiano ◽  
F. Sacilotto ◽  
G. Cillo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Fertility Preservation ◽  
Breast Cancer Patients ◽  
Brca Mutations

scholarly journals QATAR’S EXPERIENCE WITH HEREDITARY BREAST AND OVARIAN CANCER AND HIGH RISK CLINIC: A RETROSPECTIVE STUDY 2013-2016

2017 ◽  
Vol 5 (10) ◽  
pp. 184-196 ◽  
Author(s):  
Salha Mohammed Bujassoum ◽  
HekmetAbubaker Bugrein ◽  
Reem Jawad Al-Sulaiman ◽  
Hafedh Ghazouani
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Genetic Testing ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Brca Mutations ◽  
High Risk Patients ◽  
Risk Patients ◽  
High Risk Clinic

Introduction: Approximately 5%-10% of breast cancer is hereditary and BRCA1 and BRCA2 genes are responsible for most of the cases. In the State of Qatar, the cancer genetics program was established at National Center of Cancer Care and Research on 2013 which is considered the first of its kind in the region dedicated exclusively to providing genetic counseling, risk assessment and management of high risk patients and their families. In this study, we aim to describe our experience with the hereditary cancer and high risk clinic from the period of March 2013 until December 2016.Methods: In this retrospective study, a total of 697 patients were evaluated at the high risk clinic between March 2013 to December 2016. High risk patients were either placed under surveillance or offered genetic testing for the BRCA genes. Results: A total of 697 patients were evaluated at the high risk clinic in which 347 patients were considered eligible for high risk screening. 167 patients pursued genetic testing and 64 patients (38%) had BRCA mutations with BRCA1 being the most common, while 72 patients (43%) were BRCA negative. A total of 31 patients (19%) had variants of unknown significance in the BRCA genes. Most of the BRCA positive patients 63% were affected with either breast and/or ovarian cancers and were within younger age group, while 38% were unaffected. 55% of those BRCA positive affected patients had triple negative breast cancer. The prevalence of BRCA mutations among Qatari breast cancer patients reaches up to 10% while it reaches approximately 3.5% among non-Qatari breast cancer patients. Conclusion: Our program is an example of a well-established and multidisciplinary service targeted toward prevention and personalized medicine in high risk patients that goes in line with Qatar’s 2022 vision of achieving excellence in cancer care. From our unique experience, we show that BRCA mutations are prevalent among Qatari breast cancer patients reaching approximately 10% which can partially explain the young onset diagnosis of breast cancer in Qatar. With the higher awareness about our service and the recent establishment of BRCA testing at HMC, it is believed that the prevalence of BRCA is going to increase. In addition, with the introduction of multigene panel at our clinic, we believe that it will provide us with new perspective on all hereditary cancers. Our data registry on hereditary cancer syndromes will open windows for future research on cancer prevention and targeted therapies.

Sign in / Sign up

Export Citation Format

Share Document